The overview of PMDA activities

Size: px
Start display at page:

Download "The overview of PMDA activities"

Transcription

1 The overview of PMDA activities Atsushi TAMURA, Ph.D. International Coordination Officer for Medical Devices Pharmaceuticals & Medical Devices Agency

2 Who are we? PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare. Our obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices. We conduct scientific reviews of marketing authorization applications for pharmaceuticals and medical devices, monitoring of their post-marketing safety. We are also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.

3 PMDA s Mission To provide safer and more effective pharmaceuticals and medical devices as fast as we can 3

4 Philosophy of PMDA PMDA continues to improve the public health and safety of our nation by reviewing applications for marketing approval of pharmaceuticals and medical devices, conducting safety measures, and providing relief to people who have suffered from adverse drug reactions. We conduct our mission in accordance with the following principles: We pursue the development of medical science while performing our duty with greater transparency based on our mission to protect public health and the lives of our citizens. We will be the bridge between the patients and their wishes for faster access to safer and more effective drugs and medical devices. We make science-based judgments on quality, safety, and efficacy of medical products by training personnel to have the latest technical knowledge and wisdom in their field of expertise. We play an active role within the international community by promoting international harmonization. We conduct services in a way that is trusted by the public based on our experiences from the past.

5 Our Responsibilities [MHLW] Ultimate Responsibilities in policies & administrative measures [PMDA] Science base review, examination, data analysis, etc. to assist MHLW S measures

6 PMDA three major functions/tasks PMDA (Phermaceuticals and Medical Devices Agency) was established in April, 2004 to ensure the following 3 tasks to protect public health. Review and Audit for Drugs/ Medical Devices Efficacy and Safety Post- marketing Safety Operations for Drugs / Medical Devices Relief Service for ADR and Other Infectious Disease Clinical Trial Consultation Review of Efficacy and Safety Conformity Audit for Application Materials of GLP,GCP and GMP/QMS Reinforced Safety Information (Database) Scientific Review and Research for Safety Information Information Provision (via the Internet), Pharmaceutical Consultation for Consumers Provision of Medical Expenses, Disability Pensions etc. Relief Service for SMON, HIV-positive and AIDS patients 6

7 Auditor Auditor Key Organization Chart of PMDA Chief Management Officer Offices of General Affairs/ Financial Management Office of Planning and Coordination Office of International Programs Office of Reg. Sci. Operations Senior Executive Director Chief Relief Officer Office of Relief Funds Office of Review Administration Office of Review Management Chief Executive Director (Center for Product Evaluation) Office of New Drug I - V Office of Medical Devices I - III Review Department Office of OTC/Generic Drugs Office of Biologics I - II Executive Director Office of Conformity Audit (Inspections such as GLP/GCP and GPSP) Executive Director Chief Safety Officer Office of Compliance and Standards Office of Safety I - II (GMP/ QMS Inspection) Post-marketing Department 7

8 Contents 1. Organizational Updates 2. Safety Measures 3. PMDA International Vision 4. Regulatory Science 5. Science Board 8

9 1. Organizational Updates Staff Size Strengthen Review System 9

10 PMDA Staff Size Administrative part Safety Department Review Department Planned

11 Strengthen Review System in PMDA- Special Assistant for Chief Executive (Feb. 2012) Office of Review Innovation (Apr. 2012) Science Board (May 2012) 2 Deputy Directors for Center for Product Evaluation (June 2012) 11

12 New Organization (as of June 2012) - Enhance partnership with academia - Subcommittee(Drug) Science Board Subcommittee(Medical Device) Subcommittee(biologics) Subcommittee(cell-and tissue-based products) Office of Review Innovation, Director General Associate director General Deputy Associate director General Executive Director (Review Research) Secretariat Director Director, Center for product evaluation Deputy Center Director for medical Devices Review Section Chief Executive Special Assistant Senior Executive Director (Technology Management) Deputy Center Director for Cellular-and Tissue-based products Safety Section Executive Director (General Coordination) Relief Section Administration Section 12

13 To reduce Drug Submission Lag 1. Promoting Global Clinical Trial Developing Guidelines Holding MRCT Workshop 2. Consultation Pharmaceutical Affairs Consultation on R&D Strategy Prior Assessment Consultation on Drugs 3. Efforts in Regulatory Science Collaboration with Academia Establishment of the Science Board MHLW/PMDA/Academia Collaborative Study

14 2. Safety Measures New Risk Management System Electronic Medical Record Network Project for Drug Safety 14

15 Improving Safety Measures Collection of Information Analysis Assessment of Safety measure effects New Risk management system Planning and Implementation of Safety measures Hypothesis Evaluation of hypothesis Crisis management Goal Prevention of serious drug safety-related crisis from Japan Effective encouragement of proper drug use. Ensuring credibility to post-market safety management system.

16 Electronic Medical Record Network Project for Drug Safety Budget approved FY2011 Governmental to initiate Safety 10Mil. Data project The network construction will be completed by FY2013. Researchers Joint Study Collaboration Data request Collaborative Hospital Database Ethical Committee Network of the Collaborative Hospitals Database Database Quick actions Collaborative study Claim Data Ordering Data Health Records Laboratory Data Database Database Desired Outcomes: Risk & benefit review of medical technologies to provide safer healthcare. Quick and appropriate measures to ensure drug safety.

17 3. PMDA International Vision 17

18 PMDA International vision PMDA EPOCH TOWARD 2020 Concrete goals for PMDA to attain by 2020 as one of world s premier medical products regulatory agencies (Published in November 2011) 18

19 - PMDA EPOCH toward Excellence in Performance 2. Partnership with the Orient 3. Contribution to Harmonization 19

20 4. Regulatory Science MHLW/PMDA/Academia Collaborative Study Regulatory Science Cycle Promotion of Regulatory Science Program of Collaborative Graduate Schools 20

21 MHLW /PMDA /Academia Collaborative Study (MHLW FY 2012 Budget) 1.2B yen (about $15M US) Establishment of evaluation methods for safety and efficacy based on Regulatory Science Enhancement of personnel exchange among PMDA, Research Institutes, NIHS MHLW Support Research Intuitions Personnel exchange 366M yen (about $4.6M US) for; Developing guidance for innovative drug/medical device/biologics to streamline review process NIHS Develop Guidelines Cultivate Human Resource

22 Regulatory Science Cycle Advanced RS Data Acquisition Scientific Reflection Evaluation & Estimation Regulatory Action Balancing Factors 22

23 Promotion of Regulatory Science Policy recommendations released in 2011 Committee on Pharmaceutical of Science, Science Council of Japan (August 19, 2011) Regulatory Science is seen as Science that adjusts science technology outcome to it s most favorable shape in harmonization between human and society that is an essential concept to prove risk/benefit and to ensure safety of pharmaceuticals and medical devices. Target for Drug discovery Drug discovery by Academia Seeds Discovery Lead compounds Identification Optimization Valley of Death Non-clinical Trial Clinical Trial License out to Industry R&D by Industry For Developments Eying their Exits(Practical Use), for Rapid Processes Leading Collaboration to Practical Use, and for Ensuring the Efficacy and Safety with Academia Promotion of Regulatory Science Research is Essential 23

24 Program of Collaborative Graduate Schools Agreement with 12 Universities (as of June, 2012) Yamagata University Musashino University University of Tsukuba Kobe University Shujitsu University Osaka University Gifu Pharmaceutical University Gifu University Chiba University Teikyo University Yokohama City University Shizuoka Prefectural University 24

25 5 Establishment of the Science Board 25

26 Why Science Board now? With Review Goal (Time) achieved and Staffers increasing, We at PMDA are required to: 1 Provide review and consultation services with understanding of advanced technologies (antibody-based drugs, companion diagnostic drugs, ventricular assist devices, regenerative medicine, cancer vaccines, etc.). 2 Provide consultation/advice on the advanced scientific technology from the early stage of development to deliver the medicinal products utilizing advanced technologies sooner to the medicinal scene. 3 Keep close relationship with the academia to have the PMDA reviewers updated to the accelerating innovation. Science Board 26

27 Science Board and Office of Review Innovation Office of Review Innovation Director General Science Board Committee members: External experts from Academia Not involved in the Review Process of individual products Secretariat Director Secretariat Director s office Mission Reform PMDA reviews and related services based on science with consideration for actual medical practices Associate Director General Committee 1 Review policy for innovative medical products 2 Development of guidelines 3 Regulatory Science Research 4 Personnel exchanges 5 Election of External review experts 6 Improvements in the scientific aspects of review Subcommittee PMDA Offices Review Safety Deliberation on problems in each field Collaboration with PMDA working team (RS research, guideline development, etc.) Pharmaceuticals Medical Devices Bio-based products Cell- & tissue- Based products RS SGD RS: Office of Regulatory Science SGD: Office of Standards and Guidelines Development 27

28 Basic Research Seeds of new drug / medical devices originated in Japan For PMDA To Be More Science-Based Quality Tests Non-clinical tests Pharmaceutical consultation on R&D Strategy Office of Review Innovation Establishment of the Science Board The Science Board was established in May 2012 to discuss how PMDA can better cope with products with advanced scientific technology, in each developmental stage such as basic research, development support, product review, and post market safety measures. CT Clinical Trial Consultation Review Review Approve Post Marketing Post Marketing Safety Measure Offices of Review (Drugs & Medical Devices), Office of Safety Practical use Innovative medical products Board members Academia 28

29 To Improve Public Health Review Safety Relief 29

30 Thank you for your attention! URL: Atsushi TAMURA, Ph.D. International Coordination Officer for Medical Devices Pharmaceuticals & Medical Devices Agency JAPAN ( 独 ) 医薬品医療機器総合機構国際業務調整役 ( 医療機器担当 ) 田村敦史 東京都千代田区霞ヶ関 TEL 03(3506)9456 FAX 03(3506)

Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation)

Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation) Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation) * This translation of the original Japanese text is for information purposes only (in the event of inconsistency,

More information

PMDA Update: Its current situation

PMDA Update: Its current situation PMDA Update: Its current situation and future direction Tatsuya Kondo, M.D. Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA), Japan 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam

More information

Role and Vision of PMDA

Role and Vision of PMDA Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s

More information

Direct Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Direct Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Direct Patient ADR reporting system in Japan Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions expressed in the following PowerPoint

More information

GCP Inspection by PMDA

GCP Inspection by PMDA 2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,

More information

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made

More information

Forward looking approaches & its Experiences of PMDA's ATC

Forward looking approaches & its Experiences of PMDA's ATC 6 th Asia Partnership Conference of Pharmaceutical Associations, Tokyo, 5 th April 2017 Forward looking approaches & its Experiences of PMDA's ATC Junko Sato, PhD Office Director, Office of International

More information

II. OPERATION RESULTS / ACHIEVEMENT OF FY 2005

II. OPERATION RESULTS / ACHIEVEMENT OF FY 2005 II. OPERATION RESULTS / ACHIEVEMENT OF FY 2005 PART 1. IMPROVEMENT IN OVERALL OPERATIONS AND SERVICE QUALITY OF THE AGENCY (1) Development and Implementation of 2005 Fiscal Year Plan The Agency is required

More information

Current status on Adverse Event Reporting in Japan

Current status on Adverse Event Reporting in Japan Current status on Adverse Event Reporting in Japan Iku Mitta Safety Reports Management Division, Office of Safety I PMDA 1 Abbreviation ADR: Adverse Drug Reaction DB: Database EPPV:Early Post-Marketing

More information

PMDA EPOCH Toward 2020

PMDA EPOCH Toward 2020 PMDA International Vision PMDA EPOCH Toward 2020 As one of the world s top three medical products regulatory agencies comparable to its American and European counterparts, PMDA aims to: 1. Secure the highest

More information

Post Market Surveillance and Vigilance in Japan. Medical Device Safety Division, Office of Safety I

Post Market Surveillance and Vigilance in Japan. Medical Device Safety Division, Office of Safety I Post Market Surveillance and Vigilance in Japan Medical Device Safety Division, Office of Safety I 1 Overview of Adverse Event Reporting 医療機関 Healthcare professionals /facilities 2. Investigation 3. Investigation

More information

Why do we need an addendum to ICH E6?

Why do we need an addendum to ICH E6? Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in

More information

How Will Patient Centricity be Captured in the Japanese HTA and Healthcare Reform? View from the Japanese Academia Side

How Will Patient Centricity be Captured in the Japanese HTA and Healthcare Reform? View from the Japanese Academia Side How Will Patient Centricity be Captured in the Japanese HTA and Healthcare Reform? View from the Japanese Academia Side Shunya Ikeda, MD International University of Health and Welfare 患者中心 Kanja-chushin

More information

Medical Innovation as a National Strategy

Medical Innovation as a National Strategy Medical Innovation as a National Strategy March 18, 2013 Hideaki Nakagaki Deputy General, Office of Healthcare Policy Cabinet Secretariat Provisional Translation 1 Establishment of Office of Healthcare

More information

International trend on medical device regulatory convergence

International trend on medical device regulatory convergence International trend on medical device regulatory convergence Mari Shirotani, Ph.D. Division Director, Office of International Programs Pharmaceuticals and Medical Devices Agency (PMDA) 1st December, 2017

More information

Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA

Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training

More information

Quality Risk Management ICH Q9

Quality Risk Management ICH Q9 Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation

More information

Section 3. Organization of the MOD/SDF

Section 3. Organization of the MOD/SDF Part II The Basics of Japan s Defense Policy Section 3. Organization of the MOD/SDF The Self-Defense Forces (SDF), the core of Japan s defense capability, is a specialist organization that plays the most

More information

Reform of Japan s Nuclear Safety Regulation

Reform of Japan s Nuclear Safety Regulation Reform of Japan s Nuclear Safety Regulation January, 2012 The nuclear accident at TEPCO s Fukushima Dai-ichi Nuclear Power Stations severely damaged society, economy and people s mind. Especially in Fukushima

More information

Pharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA

Pharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA Pharmacovigilance: The patient s Perspective Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA Scope of presentation Why is Pharmacovigilance important for patients?

More information

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Notification number: 0427-1 April 27, 2015 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Notification

More information

Points to Consider regarding the Notification and Publication of Package Insert Language

Points to Consider regarding the Notification and Publication of Package Insert Language Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Safety Division, Pharmaceutical Safety and Environmental Health Office of Safety I Bureau This English version

More information

Development and Promotion of Nursing-Care Robots

Development and Promotion of Nursing-Care Robots July, 16, 2017 Development and Promotion of Nursing-Care Robots Japan Robot Revolution Policy and its Impact on the Application of Robots in Elderly Care Takeshi Kobayashi Senior Officer for welfare equipment

More information

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) New Streams of Risk Management Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are

More information

Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs. Attached Documents

Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs. Attached Documents Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs Attached Documents 1. Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs

More information

Invitation to Apply for Partnering Forum 2007

Invitation to Apply for Partnering Forum 2007 Invitation to Apply for Partnering Forum 2007 We are proud to announce that The International Life Science Partnering Forum KOBE/HYOGO 2007, which is an International Business Match Making Event for life

More information

LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.

LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner

More information

AST Research Network Career Development Grants: 2019 Faculty Development Research Grant

AST Research Network Career Development Grants: 2019 Faculty Development Research Grant AST Research Network Career Development Grants: 2019 Faculty Development Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants

More information

FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY

FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY The third APEC High Level Meeting on Health and the Economy (HLM3) was held in Nusa Dua, Bali, Indonesia, on 24-25 September 2013.

More information

European IVD Regulations and Risk Based Classification. An Overview for Global Quality Professionals

European IVD Regulations and Risk Based Classification. An Overview for Global Quality Professionals European IVD Regulations and Risk Based Classification An Overview for Global Quality Professionals Anna Sadio IVD Technical Expert/Project Manager Oct 2013 Caution The new regulations are draft and subject

More information

MRC Funding and Translational Research. Dr Catriona Crombie

MRC Funding and Translational Research. Dr Catriona Crombie MRC Funding and Translational Research Dr Catriona Crombie Medical Research Council The Medical Research Council is dedicated to improving human health through the best scientific research. Its work, on

More information

Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO

Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management Carolyn Mentzer Chief, QARCO 301-619-3422 Who We Are and What We Do USAMRIID s mission is to conduct basic and applied

More information

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH

More information

Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.

Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess. Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess. Number Outcome SBA SBA-1 SBA-1.1 SBA-1.2 SBA-1.3 SBA-1.4 SBA-1.5 SBA-1.6 SBA-1.7

More information

UC HEALTH. 8/15/16 Working Document

UC HEALTH. 8/15/16 Working Document 1) UC Health Mission Our mission is to make health care better. Each UC health system works to advance this mission in its community and as a system of health systems, we work together to catalyze innovation

More information

o o o o o 2014 Application Form Congratulations, you have been selected to apply for the Lilly Innovation Fellowship Award. This is a competitive Award program designed to identify, recognize

More information

AST Research Network Career Development Grants: 2019 Fellowship Research Grant

AST Research Network Career Development Grants: 2019 Fellowship Research Grant AST Research Network Career Development Grants: 2019 Fellowship Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants are

More information

Activities of the Japan Medical Association Team in Response to the Great East Japan Earthquake

Activities of the Japan Medical Association Team in Response to the Great East Japan Earthquake Conferences and Lectures Special Feature: JMA Symposium on Health Policy Disaster Medicine and Medical Associations Activities of the Japan Medical Association Team in Response to the Great East Japan

More information

European Patients Academy (EUPATI) Update

European Patients Academy (EUPATI) Update European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to

More information

Information Brochure Professional Certificate in Pharmacovigilance

Information Brochure Professional Certificate in Pharmacovigilance Information Brochure Professional Certificate in Pharmacovigilance Catalyst Clinical Services Pvt. Ltd. Unit No. 11, CSC-12, Block D1, Sector-16, Rohini, Delhi - 110089 (India) M: +91 9818356273 Email:

More information

Special session on Ebola. Agenda item 3 25 January The Executive Board,

Special session on Ebola. Agenda item 3 25 January The Executive Board, Special session on Ebola EBSS3.R1 Agenda item 3 25 January 2015 Ebola: ending the current outbreak, strengthening global preparedness and ensuring WHO s capacity to prepare for and respond to future large-scale

More information

UMMS / UMMHC Academic Health Sciences Center

UMMS / UMMHC Academic Health Sciences Center UMMS / UMMHC Academic Health Sciences Center Joint Strategic Plan 2014 2020 FINAL DRAFT August 21, 2014 We are a leading academic health sciences center, consisting of the University of Massachusetts Medical

More information

WHO's response to the Fukushima Daiichi NPP accident (2012) Seminar on the recovery and reconstruction of Fukushima, 3 September 2014, Geneva

WHO's response to the Fukushima Daiichi NPP accident (2012) Seminar on the recovery and reconstruction of Fukushima, 3 September 2014, Geneva WHO's response to the Fukushima Daiichi NPP accident (2012) 1 Seminar on the recovery and reconstruction of Fukushima, 3 September 2014, Geneva WHO's role in Radiation Emergency Response WHO Constitution

More information

2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program

2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program 2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program Release Date: November 3, 2017 Application Due Date: February

More information

SITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL. Instruction for respondents

SITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL. Instruction for respondents SITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL What is the aim of this questionnaire? Instruction for respondents Every country is different. The way that your health system is designed, how

More information

Public health, innovation and intellectual property: global strategy and plan of action

Public health, innovation and intellectual property: global strategy and plan of action EXECUTIVE BOARD EB126/6 126th Session 3 December 2009 Provisional agenda item 4.3 Public health, innovation and intellectual property: global strategy and plan of action Report by the Secretariat 1. The

More information

Regulatory Control of Diagnostics in Tanzania. Hiiti Sillo Ag. Director General Tanzania Food and Drugs Authority

Regulatory Control of Diagnostics in Tanzania. Hiiti Sillo Ag. Director General Tanzania Food and Drugs Authority 6 th Consultative Stakeholders Meeting on UN PQ of Medicines, Diagnostics and Vaccines 4-5 April, 2011, Geneva, Switzerland Regulatory Control of Diagnostics in Tanzania Hiiti Sillo Ag. Director General

More information

Consideration on Global Harmonization

Consideration on Global Harmonization ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International

More information

Knowledge Cluster Initiative

Knowledge Cluster Initiative Knowledge Cluster Initiative -present state & issues- Yasushi Taguchi Director Office for the promotion of Regional R&D Activities Science and Technology Policy Bureau MEXT Ministry of Education, Culture,

More information

ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM

ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities

More information

Content Sheet 11-1: Overview of Norms and Accreditation

Content Sheet 11-1: Overview of Norms and Accreditation Content Sheet 11-1: Overview of Norms and Accreditation Role in quality management system Assessment is the means of determining the effectiveness of a laboratory s quality management system. Standards,

More information

Audits/Inspections Be Prepared for Anything

Audits/Inspections Be Prepared for Anything Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary

More information

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions

More information

Break the cultural Great Wall. By Rong Hui Gao M.D. MBA 25 Feb, 2010

Break the cultural Great Wall. By Rong Hui Gao M.D. MBA 25 Feb, 2010 Break the cultural Great Wall By Rong Hui Gao M.D. MBA 25 Feb, 2010 1 East Meets West 礼 Respect 信 Trust 求同 Homogeneous 关系 Relationship 领导力 Leadership 创新 Innovation 求异 Individuality 信誉 Credibility 2 China

More information

High Level Pharmaceutical Forum

High Level Pharmaceutical Forum High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following

More information

12.0 Investigator Responsibilities

12.0 Investigator Responsibilities 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational

More information

Roles & Responsibilities of Investigator & IRB

Roles & Responsibilities of Investigator & IRB Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference

More information

HEALTH POLICY, LEGISLATION AND PLANS

HEALTH POLICY, LEGISLATION AND PLANS HEALTH POLICY, LEGISLATION AND PLANS Health Policy Policy guidelines for health service provision and development have also been provided in the Constitutions of different administrative period. The following

More information

Jesuits maintain the largest, most extensive and oldest higher education system in the world

Jesuits maintain the largest, most extensive and oldest higher education system in the world For 450 years Pontifical Gregorian University Rome, Italy (1551) Messina Sicily (1548) St. Paul's College Macau, China (1594) Medical College Bahia, Brazil (1556) St. Paul's College Goa, India (1542) Jesuits

More information

STUDY PLAN Master Degree In Clinical Nursing/Critical Care (Thesis )

STUDY PLAN Master Degree In Clinical Nursing/Critical Care (Thesis ) STUDY PLAN Master Degree In Clinical Nursing/Critical Care (Thesis ) I. GENERAL RULES AND CONDITIONS:- 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of specialty

More information

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and

More information

Contributing to the World Peace and Promoting Effective Security Export Control CENTER FOR INFORMATION ON SECURITY TRADE CONTROL

Contributing to the World Peace and Promoting Effective Security Export Control CENTER FOR INFORMATION ON SECURITY TRADE CONTROL Contributing to the World Peace and Promoting Effective Security Export Control CENTER FOR INFORMATION ON SECURITY TRADE CONTROL CISTEC Spirit Creativity International Sp Contents Introduction 1 History

More information

Mission. History. Cleared for public release. SAF/PA Case Number

Mission. History. Cleared for public release. SAF/PA Case Number U.S. Air Force Scientific Advisory Board The U.S. Air Force Scientific Advisory Board (SAB) is a Federal Advisory Committee chartered by the Secretary of Defense that consists of civilian experts appointed

More information

Pablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN

Pablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,

More information

Trends in the development of regulatory systems by the example of ICH countries

Trends in the development of regulatory systems by the example of ICH countries Trends in the development of regulatory systems by the example of ICH countries Author: Pär Tellner, Member of ICH Management Committee (ICH MC), EFPIA * Date: 27/08/2018 * GMP conference, Kazan, Russia

More information

NSF: Form and Function

NSF: Form and Function NSF: Form and Function C. Susan Weiler Office for Earth System Studies Whitman College DISCCRS VII Symposium, Colorado Springs, CO, October, 2012 Vannevar Bush and Science: The Endless Frontier A Report

More information

GAO ANTHRAX VACCINE. Changes to the Manufacturing Process. Testimony

GAO ANTHRAX VACCINE. Changes to the Manufacturing Process. Testimony GAO United States General Accounting Office Testimony Before the Subcommittee on National Security, Veterans Affairs, and International Relations, Committee on Government Reform, House of Representatives

More information

Helping physicians care for patients Aider les médecins à prendre soin des patients

Helping physicians care for patients Aider les médecins à prendre soin des patients CMA s Response to Health Canada s Consultation Questions Regulatory Framework for the Mandatory Reporting of Adverse Drug Reactions and Medical Device Incidents by Provincial and Territorial Healthcare

More information

Towards Quality Care for Patients. National Core Standards for Health Establishments in South Africa Abridged version

Towards Quality Care for Patients. National Core Standards for Health Establishments in South Africa Abridged version Towards Quality Care for Patients National Core Standards for Health Establishments in South Africa Abridged version National Department of Health 2011 National Core Standards for Health Establishments

More information

The Australian Pancreatic Cancer Genome Initiative (APGI)

The Australian Pancreatic Cancer Genome Initiative (APGI) The Australian Pancreatic Cancer Genome Initiative (APGI) BioSpecimen & Data Access Policy Version 4.4 Scope: This policy covers all requests for access to BioSpecimens and clinical data managed by the

More information

Brooks College of Health Nursing Course Descriptions

Brooks College of Health Nursing Course Descriptions CATALOG 2010-2011 Undergraduate Information Brooks College of Health Nursing Course Descriptions NSP3486: AIDS: A Health Perspective 3 This course provides a comprehensive view of the spectrum of HIV infection

More information

Public Health Subcommittee

Public Health Subcommittee Public Health Subcommittee Decision Brief: Improving Defense Health Program Medical Research Processes Defense Health Board June 26, 2017 1 Overview Tasking Membership Timeline Findings & Recommendations

More information

Action Plan for Strengthening Measures on Emerging Infectious Diseases (Outline)

Action Plan for Strengthening Measures on Emerging Infectious Diseases (Outline) Action Plan for Strengthening Measures on Emerging Infectious Diseases (Outline) Spread of Ebola Virus Disease in West Africa A significant impact on people s daily lives and economic activities

More information

Detailed planning for secure health care delivery

Detailed planning for secure health care delivery Detailed planning for secure health care delivery Country: Japan Partner Institute: Kinugasa Research Institute, Ritsumeikan University, Kyoto Survey no: (9)2007 Author(s): Matsuda, Ryozo Health Policy

More information

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Dr. Rania Bader, HRH2030 Health Workforce Competency Lead HRH2030 The Human Resources for Health (HRH2030) is a

More information

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP

More information

Quality Improvement Plan

Quality Improvement Plan Quality Improvement Plan Agency Mission: The mission of MMSC Home Care Plus is to at all times render high quality, comprehensive, safe and cost-effective home health care and public health services to

More information

Nurse Practitioner Student Learning Outcomes

Nurse Practitioner Student Learning Outcomes ADULT-GERONTOLOGY PRIMARY CARE NURSE PRACTITIONER Nurse Practitioner Student Learning Outcomes Students in the Nurse Practitioner Program at Wilkes University will: 1. Synthesize theoretical, scientific,

More information

ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan

ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international

More information

Leadership and Cesarean Section Reduction. Funding for the development of this toolkit was provided by the California Health Care Foundation

Leadership and Cesarean Section Reduction. Funding for the development of this toolkit was provided by the California Health Care Foundation Leadership and Cesarean Section Reduction Funding for the development of this toolkit was provided by the California Health Care Foundation The California Health Care Foundation is dedicated to advancing

More information

SOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils

SOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:

More information

FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice

FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice FDA Outlook 2017 Seth A. Mailhot, Partner Lead, FDA Regulatory Practice January,25, 2017 Overview Gaming the Elections Influence on FDA in 2017 Potential Congressional Activity PDUFA VI and MDUFA IV Restructuring

More information

Impact the World: Human Health President s Report to the Board of Trustees November 10, 2017

Impact the World: Human Health President s Report to the Board of Trustees November 10, 2017 Impact the World: Human Health President s Report to the Board of Trustees November 10, 2017 Penn State s Vision To be a leader in promoting quality of life through comprehensive approaches to enhancing

More information

CFP in Japan -New step for privatization of CFP program-

CFP in Japan -New step for privatization of CFP program- CFP in Japan -New step for privatization of CFP program- Asami Miyake Japan Environmental Management Association for Industry (JEMAI) 17 April, 2012 PCF World Summit Today s contents Introduction of JEMAI

More information

TARGETED RFA IN PROSTATE CANCER RESEARCH Predictive Markers

TARGETED RFA IN PROSTATE CANCER RESEARCH Predictive Markers TARGETED RFA IN PROSTATE CANCER RESEARCH Predictive Markers Revised 20180504 *see p. 3 sentence revised Part 1: Overview Information Participating Organization(s) Funding Opportunity Title Description

More information

WORLD HEALTH ORGANIZATION

WORLD HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB115/6 115th Session 25 November 2004 Provisional agenda item 4.3 Responding to health aspects of crises Report by the Secretariat 1. Health aspects of crises

More information

Health care innovations and medical technology: reaching the unreached

Health care innovations and medical technology: reaching the unreached Health care innovations and medical technology: reaching the unreached Context setting India ill equipped to meet the growing needs of the population. Brilliance and talent in medicine, engineering & basic

More information

Coastal Medical, Inc.

Coastal Medical, Inc. A Culture of Collaboration The Organization Physician-owned group Currently 19 offices across the state of Rhode Island and growing 85 physicians, 101 care providers The Challenge Implement a single, unified

More information

Federal Research: Neuroscience and the BRAIN Initiative

Federal Research: Neuroscience and the BRAIN Initiative Federal Research: Neuroscience and the BRAIN Initiative Lewis-Burke Associates, LLC June 1,2017 About Lewis-Burke Twenty-eight policy experts with range of expertise/backgrounds allow multi-layered issue

More information

AREA STUDIES JAPAN Protection and Promotion of Human Health in Japan - R. Kishi, J. Goshima and A. Isu

AREA STUDIES JAPAN Protection and Promotion of Human Health in Japan - R. Kishi, J. Goshima and A. Isu PROTECTION AND PROMOTION OF HUMAN HEALTH IN JAPAN R. Kishi, J. Goshima and A. Isu Department of Public Health, Hokkaido University School of Medicine, Japan Keywords: administrative reform, decentralization,

More information

WYSIWYG CO., LTD. October 2015

WYSIWYG CO., LTD. October 2015 WYSIWYG CO., LTD. October 2015 CEO GREETINGS WysiWyg, since its foundation in 1994 and NASA database preparation to the present day, has always endeavored to achieve customer satisfaction with high quality

More information

CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION

CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION November 2016 ABOUT CORD The Canadian Organization for Rare Disorders (CORD) provides a strong common voice to advocate for health policy and a healthcare

More information

REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA

REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA ULAANBAATAR 2011 Abbreviations... 3 Acknowledgement... 4 Executive Summary... 5 1. General information on the assessment.... 7 1.1 Purpose of this

More information

Dr Nata Menabde. Candidate for WHO Regional Director for Europe. Excellence for Health and Equity

Dr Nata Menabde. Candidate for WHO Regional Director for Europe. Excellence for Health and Equity Dr Nata Menabde Candidate for WHO Regional Director for Europe Excellence for Health and Equity A message from Dr Nata Menabde With this message, I would like to let you know of my candidacy for the position

More information

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics 30.1.2017 Oslo 3.2.2017 O. Konttinen 1 Background Based on directive 2001/20/EC of the clinical trials on medicinal

More information

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION OF CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS IN MALAWI 1. INTRODUCTION The clinical trial application must undergo a

More information

NFMRI. National Foundation for Medical Research and Innovation. Impact giving Advancing medical innovations

NFMRI. National Foundation for Medical Research and Innovation. Impact giving Advancing medical innovations NFMRI National Foundation for Medical Research and Innovation Impact giving Advancing medical innovations Philanthropy has the freedom to think different, do different, & make a difference. Medical innovation

More information

Strategies to Improve the Use of Medicines Standard Treatment Guidelines

Strategies to Improve the Use of Medicines Standard Treatment Guidelines Strategies to Improve the Use of Medicines Standard Treatment Guidelines Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control

More information

New European Union Clinical Trial Regulations

New European Union Clinical Trial Regulations New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer

More information

November Innovative Medicines Initiative (IMI) Intellectual Property (IP) Policy. Guidance Note for IMI Applicants and Participants

November Innovative Medicines Initiative (IMI) Intellectual Property (IP) Policy. Guidance Note for IMI Applicants and Participants Innovative Medicines Initiative (IMI) Intellectual Property (IP) Policy Guidance Note for IMI Applicants and Participants 1. INTRODUCTION The purpose of this guidance note 1 is: - to clarify the IMI IP

More information